People searching for a BPC-157 dosage for tendon healing are usually really asking a different question: does the evidence support using it at all, and if so, who decides how. Here is what the literature says, and why the "how much" part belongs to a provider conversation rather than a search result.
What we know from the literature
BPC-157 is a synthetic pentadecapeptide studied almost entirely in preclinical models of tendon, ligament, and soft-tissue injury. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine describes its proposed mechanisms as involving VEGFR2-mediated angiogenesis and nitric oxide signaling through the Akt-eNOS pathway, both plausible contributors to how new blood vessels form in poorly vascularized tissue like tendon (Current Reviews in Musculoskeletal Medicine, 2025). The same review notes these findings come predominantly from animal models rather than large controlled human trials.
That distinction matters more than it might seem. Educational content like this can summarize what has been observed in rodent tendon-injury models, but it cannot responsibly translate that into a specific number of milligrams for a specific person, because that translation has not been established in human trials at any dose. Outcomes are individual, and the honest position is that BPC-157’s dosing in human clinical use remains a matter of clinical judgment rather than a settled protocol from the literature.
Why dosage ranges you see online should not be trusted at face value
Many of the specific mg-per-day or mg/kg figures circulating for BPC-157 originate from extrapolations of animal-model doses, from anecdotal community reporting, or from sources with no connection to a clinical evaluation. None of that constitutes a validated human dosing protocol. The ranges reported in the published literature describe doses given to rodents in specific injury models, not doses proven safe or effective in people; a US-licensed provider will individualize any prescription based on your evaluation, taking into account your health history, weight, and the reason you are seeking care, rather than applying a number copied from a study designed for a different species and purpose. Individual results vary, which is exactly why that individualization step matters.
This is also why Van Peptides’ telehealth pathway routes every prescription through an evaluation first. Not medical advice: a provider who can review your full history is in a fundamentally different position than an article to make that call, and it is one of the main reasons prescription-only compounded peptides differ from over-the-counter products.
What a provider actually considers
A licensed provider weighs the existing preclinical evidence for BPC-157 against your specific history, including current medications, prior injuries, and other health conditions, before deciding whether a prescription is appropriate at all, let alone what it should look like. Because most of the supporting data is preclinical, a thoughtful provider will also set expectations conservatively rather than promise a specific timeline or outcome. Individual results vary, and that variability is part of why generic dosage figures pulled from a rat study are not a substitute for that conversation.
How to access it responsibly
- Everything is available after a licensed-provider evaluation.
- Peptides are compounded through a US-licensed compounding pharmacy.
Sources
- Regeneration or Risk? A Narrative Review of BPC-157 for musculoskeletal applications. Current Reviews in Musculoskeletal Medicine, 2025 pmc.ncbi.nlm.nih.gov/articles/PMC12446177/